Dr Reddy's launches halometasone cream in India
Dr Reddy's Laboratories Ltd has launched Execare (halometasone cream 0.05 per cent) in India for the treatment of acute/chronic steroid responsive dermatoses and vitiligo.
Execare is a potent steroid and is recommended as an alternative to betamethasone dipropionate and mometasone furoate.
The halometasone monohydrate is known to have very good anti-inflammatory action with significant safety and tolerability profile. Halometasone acts by blocking their production, thus acting as an anti-inflammatory agent.
With this launch, Dr Reddy's becomes the first company to introduce this molecule in India, a press release said.
The topical steroid market size is about Rs 120 crore and growing at 14 per cent according to ORG figures of May 2009.
Comments